MicroRNA-206 Prevents the Pathogenesis of Hepatocellular Carcinoma Via Modulating Expression of cMet and Cdk 6
Heng Wu,J. Tao,Xiaolei Li,Tianpeng Zhang,Lei Zhao,Yao Wang,Lei Zhang,J. Xiong,Zhi Zeng,N. Zhan,C. Steer,L. Che,Mingjie Dong,Xiaomei Wang,J. Niu,Zhuoyu Li,Guiqing Yan,Xin Chen,Guisheng Song
DOI: https://doi.org/10.1002/hep.29374
2017-01-01
Abstract:Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide and therapeutic agents for this malignancy are lacking. MicroRNAs play critical roles in carcinogenesis and present tremendous therapeutic potential. Here we report that microRNA-206 is a robust tumor suppressor that plays important roles in the development of HCC by regulating cell cycle progression and cMet signaling pathway. MicroRNA-206 was under-expressed in livers of two HCC mouse models, human individuals bearing HCC, and human HCC cell lines. Combining bioinformatic prediction and molecular and cellular approaches, we identified cMET (Met protooncogene), CCND1, and CDK6 as functional targets of microRNA-206. By inhibiting expression of cMET, CCND1 and CDK6, microRNA-206 delayed cell cycle progression, induced apoptosis and impaired proliferation of three distinct human HCC cell lines. Systemic administration of microRNA-206 completely prevented HCC development in both cMyc and AKT/Ras HCC mice, while 100% of control mice died from lethal tumor burdens. Conversely, re-introduction of cMet or Cdk6 into livers of cMyc and AKT/Ras HCC mice recovered growth of HCC inhibited by microRNA-206. These results strongly suggested that cMet and Cdk6 were two functional targets that mediated the inhibitory effect of microRNA-206 on the development of HCC. MicroRNA206 overexpression demonstrated a profound therapeutic effect on HCC in xenograft and cMyc HCC mice. In summary, this study defines a potentially critical role of microRNA-206 in preventing the growth of HCC, and suggests its use as a potential therapeutic strategy for this malignancy. Page 4 of 56 Hepatology Hepatology This article is protected by copyright. All rights reserved. HCC is a very common malignant disease with more than 700,000 new patients diagnosed per year. 1 The incidence of HCC worldwide nearly matched its mortality, demonstrating the aggressive nature of this malignancy and limited therapeutic options. 1, 2 Although hepatitis B (HBV) and C (HCV) infection are the major risk factors of HCC, liver damage due to NAFLD (non-alcoholic fatty liver disease) is associated with the majority of HCC patients in the Western world. 3, 4 During the past 30 years, HCC patients have tripled due to the prevalence of obesity and its related morbidities, including NAFLD. 1 Given the limited success with chemotherapy and the insensitivity of HCC to radiotherapy, tumor extirpation represents the only choice for longterm cure. 1, 2 Unfortunately, even with successful surgical removal, the presence of NAFLD is associated with an increased recurrence of tumor. 3, 4 Continuous efforts are needed to identify new targets and molecular pathways for drug development in the treatment of HCC. MicroRNAs (miRNAs) are naturally-occurring small non-coding RNAs that function primarily by binding to the 3'-untranslated regions (3'-UTR) of specific mRNAs, which leads to either mRNA or translational pausing. 5 Accumulating evidence has shown that these small molecules play important roles in carcinogenesis, lipid metabolism and development by repressing expression of their targets. 6-8 MiRNA profiling of HCC tumors and its adjacent benign tissues identified a number of dysregulated miRNAs in HCC. 9-11 Given their critical role in carcinogenesis, 12 these miRNAs now represent novel therapeutic agents for human cancers. However, the detailed mechanism(s) by which miRNAs modulate hepatocarcinogenesis is largely unknown and miRNA therapeutic drugs for this cancer are unavailable. Amplification and overexpression of the cMYC oncogene is a frequent event in human HCC. 13, 14 In mice, overexpression of cMyc via hydrodynamic transfection leads to rapid liver tumor formation. 15 In addition, coordinated activation of AKT/mTOR and RAS/ MAPK Page 5 of 56 Hepatology Hepatology This article is protected by copyright. All rights reserved. cascades occurs in over 50% of all human HCCs, and is associated with biological aggressiveness and poor prognosis. 16 This phenotype can be recapitulated in vivo by hydrodynamically transfecting activated forms of AKT (myr-AKT) and NRas (NRas-V12) oncogenes (AKT/Ras) into the mouse liver. 16 In our previous study, we showed that all mice transfected with AKT/Ras or cMyc died by 6 to 8 weeks post-injection due to tumor burden. 15 In addition, cMyc and AKT/Ras-induced HCC in rodents recapitulate, in a highly reliable way, the phases of tumor initiation and progression that occur in humans. In this study, we used cMyc and AKT/Ras mice, xenograft tumor mice and human HCC cell lines to investigate the underlying mechanisms by which miR-206 inhibits HCC, in addition to assessing its therapeutic potential for liver cancer. Materials and Methods Construction of Expression Vectors for miR-206, AKT, Ras, cMyc, cMet, Cdk6 and Ccnd1. A 400 bp fragment containing the miR-206 precursor was amplified from human genomic DNA, inserted into a pT3-EF1α vector and referred as to pT3-EF1α-miR-206. Construction of vectors pT3-EF1α-cMyc, 15 pT3-EF1α-myr-AKT, 15 nRasV12/pT2-CAGGS, 15 pT3-EF1α-Ccnd1, 17 pT3EF1α-Cdk6, 17 pT3-EF1α-cMet, 17 and pCMV/Sleeping Beauty transposase (pCMV/SB) 15 was carried out as previously described. All the plasmids used to induce HCC in wild-type FVB/N mice were purified using the Endotoxin free Maxi prep kit (Sigma, St. Louis, MO). Construction of a Mini-circle Expression Vector for miR-206. We generated a versatile expression vector of miR-206 by cloning a human miR-206 precursor region into mini-circle vectors purchased from System Biosciences (Palo Alto, CA). A transthyretin gene (TTR) promoter was inserted upstream of the miR-206 precursor to ensure liver-specific expression of miR-206. 18 This new construct was referred to as MC-TTR-miR-206. To rule out non-specific Page 6 of 56 Hepatology Hepatology This article is protected by copyright. All rights reserved. effects of the plasmid, we generated a miR-206 mis-matched-expression vector by mutating seed region of miR-206, termed MC-TTR-miR-206-MM. To prepare mini-circle vectors, parental MC-TTR-miR-206 vector was transformed into a special host E. coli bacterial strain ZYCY10P3S2T (System Biosciences, Palo Alto, CA). All mini-circles were made based on the manufacturer’s instruction. Preparation of miR-206 Mimic. miR-206 mimic and scramble control were purchased from Creative Biogene (Shirley, NY). miR-206 mimic is chemically-modified double-strand miRNAs which can mimic mature endogenous miR-206 after transfection into cells. The antisense strand of miR-206 has 2 phosphorothioates at the 5' end, 4 phosphorothioates, 4 cholesterol groups at the 3' end, and full length nucleotide 2'-methoxy modification. Both miR-206 mimic and scramble control were formulated in 0.9% NaCl to a final concentration of 10 mg/ml. Establishment of AKT/Ras and cMyc HCC Mice. Eight week old FVB/N mice (wild-type) were obtained from Charles River (Wilmington, MA). Standard hydrodynamic injections were performed as previously described. 15 To determine the inhibitory effect of miR-206 on cMycinduced HCC, mice (n=10) were hydrodynamically injected with 5 μg pT3-EF1α-cMyc, and 10 μg pT3-EF1α-miR-206 together with 0.6 μg pCMV/SB. Control mice (n=10) were injected with 4 μg pT3-EF1α-cMyc and 10 μg pT3-EF1α together with 0.6 μg pCMV/SB. To evaluate the effect of miR-206 on AKT/Ras-induced HCC, mice (n=10) were hydrodynamically injected with 4 μg pT3EF1α-myr-AKT, 4 μg NRasV12/pT2-CAGGS, and10 μg pT3-EF1α-miR-206 together with 0.72 μg pCMV/SB. Control mice (n=10) received 4 μg pT3-EF1α-myr-AKT, 4 μg NRasV12/pT2-CAGGS, and10 μg pT3-EF1α together with 0.72 μg pCMV/SB. To examine whether cMet, Cdk6 and Ccnd1 were the functional targets of miR-206, wild-type FVB/N mice were randomly separated into five groups: Group I mice (control group, n=10) were injected Page 7 of 56 Hepatology Hepatology This article is protected by copyright. All rights reserved. with a combination of 4 μg pT3-EF1α-myr-AKT, 4 μg NRasV12/pT2-CAGGS, 10 μg pT3-EF1α and 1.12 μg pCMV/SB; Group II (n=10) were injected with a combination of 4 μg pT3-EF1αmyr-AKT, 4 μg NRasV12/pT2-CAGGS, 10 μg pT3-EF1α-miR-206, and 1.12 μg pCMV/SB. This group was used to determine whether miR-206 was able to prevent HCC development; Group III-V (n=10) received 4 μg pT3-EF1α-myr-AKT, 4 μg NRasV12/pT2-CAGGS, 10 μg pT3-EF1α-miR-206 and 1.12 μg pCMV/SB together with 10 μg pT3-EF1α-cMet, pT3-EF1αCdk6 or pT3-EF1α-Ccnd1. This Group was used to determine whether additional treatment of Ccnd1, Cdk6 or cMet expression vector was able to recover the development of HCC inhibited by miR-206. The same strategy was used to determine whether cMet, Cdk6 and Ccnd1 mediated the inhibitory effect of miR-206 on HCC in cMyc mice. The plasmid mixtures were diluted in 2 ml saline (0.9% NaCl), filtered through 0.22 μm filter, and injected into the lateral tail vein of 6 to 8-week-old FVB/N mice in 5 to 7 seconds. Mice were housed, fed, and monitored in accordance with protocols approved by the committee for animal research at the University of California, San Francisco and the University of Minnesota. Therapeutic Models of cMyc and AKT/Ras Mice. For MC-TTR-miR-206 experiments, FVB/N mice were injected with cMyc or AKT/Ras as described above. At 2 weeks post injection of AKT/Ras or cMyc, mice were treated with MC-TTR-miR-206 or MC-TTR-miR-206-MM at a dose of 1.5 mg/kg (i.v.) once a week for 4 weeks. For miR-206 mimic experiments, at 2 weeks post injection of AKT/Ras or cMyc, mice were treated with miR-206 mimic or control mimic at a dose of 10 mg/kg (i.v), twice a week for 4 weeks. Global miRNA Expression Profiling of Livers of AKT/Ras and cMyc HCC Mice. A NanoString nCounter miRNA (NanoString Technologies, Seattle, WA) assay was used to perform miRNA profiling in livers of wild-type, cMyc and AKT/Ras mice. Total RNA was Page 8 of 56 Hepatology Hepatology This article is protected by copyright. All rights reserved. extracted from frozen